We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 432

Health Law Update - January 12, 2017
  • Baker & Hostetler LLP
  • USA
  • January 12 2017

Welcome to this week's edition of the Health Law Update. In this Issue: CMS Finalizes Mandatory Cardiac and Joint Bundles But Their Future is


Biotech Patent Dispute Between Academics That Is Far From Academic
  • Baker & Hostetler LLP
  • USA
  • January 3 2017

On December 6, 2016, the parties to the complex and soon-to-be departed world of patent Interferences orally argued their positions on motions in


Post Grant Review: 112 and Eligibility Issues in Chemical and Life Sciences
  • Baker & Hostetler LLP
  • USA
  • November 28 2016

Post Grant Review (PGR) petitions are on the rise, and nearly half of all petitions to date have challenged patents in Biotechnology and Organic


Nursing Home Arbitration Ban: There’s a Line in the Sand - But the Tide May Still Come In
  • Baker & Hostetler LLP
  • USA
  • November 17 2016

On November 7, 2016 a federal judge in Mississippi granted a request to temporarily enjoin CMS from implementing a federal rule, scheduled to take


Former Tuomey CEO Settles with DOJ for $1 Million
  • Baker & Hostetler LLP
  • USA
  • November 14 2016

The U.S. Department of Justice (DOJ) recently reached a $1 million settlement with Ralph J. Cox III, the former CEO for Tuomey Health System, Inc


The 60-Day Rule: Failure to Return Overpayments Caused by Software Glitch Costs Hospital $2.95 Million
  • Baker & Hostetler LLP
  • USA
  • October 31 2016

A software glitch can be just as risky for a healthcare provider as submitting a false claim. Or so it was declared on August 24, 2016 when the U.S


Health Law Update - October 20, 2016
  • Baker & Hostetler LLP
  • USA
  • October 20 2016

The Food and Drug Administration (FDA) and National Institutes of Health (NIH) have recently finalized or signaled intent to finalize numerous


Third Circuit Sets Framework for Numerosity Requirement
  • Baker & Hostetler LLP
  • USA
  • September 14 2016

In an opinion issued yesterday, the Third Circuit provided a framework for analyzing the oft-overlooked numerosity requirement of Rule 23(a)(1). In re


Sixth Circuit Vacates Class Settlement, Finding that Sealed Documents Prevented Objectors from Assessing Settlement’s Fairness
  • Baker & Hostetler LLP
  • USA
  • September 14 2016

This summer, the Sixth Circuit rejected class action litigants’ filing of the bulk of their class settlement documents under seal. Shane Grp., Inc. v


Health Law Update - August 25, 2016
  • Baker & Hostetler LLP
  • USA
  • August 25 2016

Welcome to this week's edition of the Health Law Update. In This Issue: A Tale of Two Escobars: Federal Courts Begin Grappling with Opposing Views of